Prellis Biologics

Human Tissue Printing and Pharmaceutical Development

Company Details

Prellis Biologics is a newly-founded company developing novel technology to bioprint vascularized human tissues. Networks of small blood vessels are necessary for tissue function, homeostasis, and development. Prellis Biologics is dedicated to providing better drug testing options and tissues for human transplant, including solid organs, connective tissues (tendons, ligaments), and secretory tissues.

Our platform technology allows for development of multiple products. Initially, we will seek to create surrogate tissues for pharmaceutical testing. This will be followed by development of large-format tissue for the human transplant market.

Company People

Noelle Mullin

Noelle Mullin

Elizabeth Reynolds

Elizabeth Reynolds

Melanie Matheu

Melanie Matheu
CEO & Co-Founder

Prellis Biologics News


GET IN TOUCH WITH Prellis Biologics

Please tell us a little bit about yourself and why you'd like to get connected.

Prellis Biologics + SOSV will follow up with you via email.

** If you are interested in investing directly into SOSV's portfolio of privately held companies, or into SOSV's funds, you need to meet the SEC’s criteria for accredited investor status. As an individual, you can qualify as an accredited investor by either (a) having more than $200,000 in annual income for each of the past two years (or $300,000 with your spouse) and a reasonable expectation of earning the same this year or (b) having a net worth of at least $1 million (not including your principal residence). Learn More

You might also be interested in

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.